- Conditions
- Retinal Vasculitis
- Interventions
- aflibercept 2mg
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 290,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Tarrytown, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 118
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
- Interventions
- MHU650
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- Huntington Beach, California • Honolulu, Hawaii • Hagerstown, Maryland + 2 more
- Conditions
- Macular Edema, Branch Retinal Vein Occlusion
- Interventions
- Faricimab, Aflibercept, Sham Procedure
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 553 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more
- Conditions
- Central Retinal Vein Occlusion
- Interventions
- Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more
- Conditions
- Age-Related Macular Degeneration, Diabetic Retinopathy, Von Hippel-Lindau Syndrome, Retinal Disease, Retinal Vein Occlusion
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 2 Years to 120 Years
- Enrollment
- 650 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Macular Edema, Central Retinal Vein Occlusion
- Interventions
- Ozurdex, Ranibizumab, Combination Ozurdex with Ranibizumab PRN
- Drug
- Lead sponsor
- Valley Retina Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Lakeland, Florida • Winter Haven, Florida + 2 more
- Conditions
- Retinal Vein Occlusion, Posterior Vitreous Detachment
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Barnes Retina Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Macular Degeneration, Retinal Vein Occlusion
- Interventions
- Triamcinolone Acetonide (TAC-PF)
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- 4 mg CLS-TA, Sham, IVT aflibercept
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Beverly Hills, California • San Diego, California + 11 more
- Conditions
- Retinal Vein Occlusion
- Interventions
- Dexamethasone intravitreal implant, Monthly Ranibizumab
- Drug
- Lead sponsor
- Brian Burke, MPH
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusions
- Interventions
- LKA651, Sham Comparator
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 5
- States / cities
- Pasadena, California • Fort Myers, Florida • Miami, Florida + 2 more
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- Intravitreal injection of ranibizumab .3 dose, Intravitreal injection of Ranibizumab .5 dose
- Drug
- Lead sponsor
- Peter A Campochiaro, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
- Interventions
- Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel, Acuvail, Intra-vitreal Anti-VEGF Drug
- Procedure · Drug
- Lead sponsor
- Retina Vitreous Associates of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Clearwater, Florida
- Conditions
- Retinal Vein Occlusion
- Interventions
- Nicotinic acid, Prednisolone acetate
- Drug
- Lead sponsor
- Palo Alto Medical Foundation
- Other
- Eligibility
- Not listed
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
- Interventions
- Remigromig, Aflibercept 2.0 mg
- Drug
- Lead sponsor
- EyeBiotech Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 55
- States / cities
- Scottsdale, Arizona • Glendale, California • Modesto, California + 34 more
- Conditions
- Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion (RVO)
- Interventions
- Iheezo, Lidocaine pledget
- Drug
- Lead sponsor
- Retina Consultants of Delmarva
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Easton, Maryland
- Conditions
- Retinal Vein Occlusion
- Interventions
- AKB-9778
- Drug
- Lead sponsor
- Aerpio Therapeutics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Glaucoma
- Interventions
- Apraclonidine 1.0% ophthalmic solution
- Drug
- Lead sponsor
- Retina Consultants of Delmarva
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Easton, Maryland
- Conditions
- Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion, Retinal Vein Occlusion, Depression
- Interventions
- ranibizumab (Lucentis)
- Drug
- Lead sponsor
- Retina Associates of Cleveland, Inc
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Central Retinal Vein Occlusion
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- California Retina Consultants
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 4
- States / cities
- Bakersfield, California • Oxnard, California • Santa Barbara, California + 1 more
- Conditions
- Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Interventions
- Varying needle size with intravitreal ranibizumab or aflibercept
- Procedure
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Macular Edema, Cystoid, Retinal Vein Occlusion
- Interventions
- Standard Care, intravitreal triamcinolone injection
- Other · Drug
- Lead sponsor
- The Emmes Company, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 682 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Retinal Vein Occlusions
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Retinal Vein Occlusion
- Interventions
- Ranibizumab (Lucentis )
- Drug
- Lead sponsor
- Vitreous -Retina- Macula Consultants of New York
- Other
- Eligibility
- Not listed
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York